Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

 4,250.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 4,500.00
  • 52 Week Low: 2,635.00
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 801
  • Market Cap: £221.33m

Bioventix full-year revenue and profits improve

By Josh White

Date: Monday 21 Oct 2019

LONDON (ShareCast) - (Sharecast News) - Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, reported a 6% improvement in revenue for the year on Monday, to £9.3m.
The AIM-traded firm said its profit before tax rose 1% in the year ended 30 June to £7m, while its cash fell £0.5m to £6.5m.

Its board declared a second interim dividend of 43p per share, up from 36p in the prior year, and a special dividend of 47p per share, down from 55p year-on-year.

"Looking ahead to the future, we keenly anticipate the roll-out of high sensitivity troponin assays and modest growth from additional vitamin D and other antibody sales and royalties," said the Bioventix board in its statement.

"Beyond that, growth will be linked not only to the troponin project but also our continued research activities as we look to seed additional projects that will germinate in the period 2025-2030 to create additional shareholder value."

As at 1113 BST, shares in Bioventix were down 4.24% at 3,409p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 4,250.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 4,500.00
52 Week Low 2,635.00
Volume 801
Shares Issued 5.21m
Market Cap £221.33m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
98.61% below the market average98.61% below the market average98.61% below the market average98.61% below the market average98.61% below the market average
92.86% below the sector average92.86% below the sector average92.86% below the sector average92.86% below the sector average92.86% below the sector average
Price Trend
86.21% above the market average86.21% above the market average86.21% above the market average86.21% above the market average86.21% above the market average
61.40% above the sector average61.40% above the sector average61.40% above the sector average61.40% above the sector average61.40% above the sector average
Income
77.08% below the market average77.08% below the market average77.08% below the market average77.08% below the market average77.08% below the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Growth
34.37% above the market average34.37% above the market average34.37% above the market average34.37% above the market average34.37% above the market average
8.57% above the sector average8.57% above the sector average8.57% above the sector average8.57% above the sector average8.57% above the sector average

Bioventix Dividends

  Latest Previous
  Interim Final
Ex-Div 09-Apr-20 31-Oct-19
Paid 28-Apr-20 15-Nov-19
Amount 36.00p 43.00p

Trades for 03-Jul-2020

Time Volume / Share Price
16:02 100 @ 4,250.00p
15:27 115 @ 4,200.00p
15:17 118 @ 4,230.00p
15:13 23 @ 4,232.00p
15:10 7 @ 4,232.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
Finance Director Treena Joan Turner
CFO Bruce Hiscock

Top of Page